Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09XIZ
|
|||
| Former ID |
DNCL002370
|
|||
| Drug Name |
JNJ-26481585
|
|||
| Synonyms |
875320-29-9; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; UNII-9BJ85K1J8S; Quisinostat (JNJ-26481585); JNJ26481585; 9BJ85K1J8S; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Advanced stage follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 2 | [1] | |
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [2], [3] | ||
| Company |
Janssen Research & Development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H26N6O2
|
|||
| Canonical SMILES |
CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO
|
|||
| InChI |
1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)
|
|||
| InChIKey |
PAWIYAYFNXQGAP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 875320-29-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16640562, 23662539, 42656475, 80686572, 99437202, 124756995, 125163800, 134964409, 136340274, 136367295, 137574407, 144116093, 152344185, 160687244, 160830062, 162037431, 162108664, 162202708, 163094379, 163312351, 163394407, 163842923, 164193969, 172919123, 174006335, 177748745, 185992949, 187051805, 188899585, 198951338, 202535632, 204363605, 223601329, 223705149, 228477766, 245359853, 249867668, 250212580, 252070148, 252215623, 252440486
|
|||
| ChEBI ID |
CHEBI:94771
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histone deacetylase (HDAC) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01486277) A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7503). | |||
| REF 3 | JNJ-26481585, a novel "second-generation" oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res. 2009 Nov 15;15(22):6841-51. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.